Shares of the two largest kidney care companies in the United States, DaVita HealthCare Partners Inc (NYSE:DVA) and Fresenius Medical Care AG & Co.
Keep Reading →
July 8 - News
When it comes to investing for the long term, sometimes companies that are thought of as “stable” or “boring” turn out to be the best thing for your portfolio.
Keep Reading →
July 5 - News
When you are looking to add a biotech stock to your portfolio, most of the small cap biotech stocks have a small-sized pipeline.
Keep Reading →
July 5 - News
When it comes to investing, obviously making money is key and the best way to make money is to find the most profitable company set to generate huge amounts of cash in the future...
Keep Reading →
July 5 - News
Love it or hate it, the Patient Protection and Affordable Care Act -- commonly referred to as Obamacare -- changes the health care landscape.
Keep Reading →
July 5 - News
After all of the hype and hoopla over Pfizer Inc.
Keep Reading →
July 3 - News
When looking for the best dividend stocks, it's usually best to not chase the highest dividend.
Keep Reading →
July 2 - News
Over the last three decades I have seen my share of bull and bear markets.
Keep Reading →
July 1 - News
The wealth-building power of compound interest will never cease to amaze me.
Keep Reading →
July 1 - News
Merck & Co., Inc. (NYSE:MRK) has had its fair share of bad news recently. Shares have pulled back around 5% in June.
Keep Reading →
July 1 - News
To prove my point, I looked at the multi-year chart and picked out some of the peaks.
Keep Reading →
July 1 - News
Companies know that to attract regular income-seeking investors, it helps to pay out high dividends.
Keep Reading →
July 1 - News
Merck & Co., Inc. (NYSE:MRK) stock has become dependent on its diabetes drug Januvia over the past couple of years for revenue growth.
Keep Reading →
July 1 - News
An entity with deep pockets is looking to buy boatloads of Pfizer Inc. (NYSE:PFE) stock. And we're talking yacht-sized boatloads -- not canoe-sized ones.
Keep Reading →
July 1 - News
If you owned Johnson & Johnson (NYSE:JNJ) stock at the beginning of 2013, you're sitting atop gains of more than 20% right now.
Keep Reading →
June 28 - News
Enterprise value is a measure of a company's value.
Keep Reading →
June 28 - News
On June 24, the Food and Drug Administration issued “bioequivalence recommendations” for 15 active ingredients used in prescription medications.
Keep Reading →
June 28 - News
After a series of failures, one is forced to wonder whether the medical fraternity, including the research and development wing of Eli Lilly & Co.
Keep Reading →
June 27 - News
After the failure of its pipeline products for Alzheimer’s and rheumatoid arthritis, the drug giant Eli Lilly & Co. (NYSE:LLY) finally has some good news to report.
Keep Reading →
June 27 - News
Investing in biotech companies can be risky; developing new drugs is a long, expensive, and uncertain process, and there is always considerable regulatory risk in the industry...
Keep Reading →
June 26 - News
Stocks have taken a beating over the past two weeks, but Wall Street's getting a welcome moment of respite today.
Keep Reading →
June 25 - News
A director at Deloitte Services LP and co-author of The Three Rules: How Exceptional Companies Think, Michael Raynor joins The Fool to share his findings about what makes a company...
Keep Reading →
June 25 - News
Blame it on a "case of the Mondays" or perhaps a rough night out on the town, but for many of us getting a good night's rest isn't nearly as simple as it sounds.
Keep Reading →
June 25 - News
Pfizer Inc. (NYSE:PFE) was in 81 hedge funds' portfolio at the end of the first quarter of 2013. PFE shareholders have witnessed an increase in hedge fund interest recently.
Keep Reading →
June 24 - News
One of the reasons investors regard the 30 stocks in the Dow Jones Industrial Average 2 Minute (INDEXDJX:.DJI) as blue-chip giants is that all 30 of them pay dividends.
Keep Reading →
June 24 - News
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors.
Keep Reading →
June 20 - News
A new Supreme Court ruling presents pharmaceutical companies with a tough choice -- stop paying generic-drug producers to withhold generic options from the market, or risk getting...
Keep Reading →
June 20 - News
A director at Deloitte Services LP and coauthor of The Three Rules: How Exceptional Companies Think, Michael Raynor joins the Fool to share his findings about what makes a company...
Keep Reading →
June 20 - News
It started running in 1980, when a series of interest rate increases by the Federal Reserve finally broke the back of inflation, and it galloped onward for more than three decades...
Keep Reading →
June 19 - Stock Analysis
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
June 19 - News
A spate of 10 biotechs went public this year, raising over $725 million.
Keep Reading →
June 19 - News
Investors can never predict whether the market will rise or fall on any given day, but lately, a pretty good bet has been to expect some substantial volatility in one direction...
Keep Reading →
June 19 - News
Wall Street is in a good mood again a day before the conclusion of the Federal Reserve's policy meeting.
Keep Reading →
June 18 - News
London-based pharmaceutical giant AstraZeneca plc (ADR) (NYSE:AZN) recently announced that it had agreed to purchase U.S.-based lung-drug manufacturer Pearl Therapeutics for at...
Keep Reading →
June 18 - News
About a third of American adults have high LDL cholesterol -- that's the bad kind -- but less than half of adults with high LDL seek treatment, according to the Centers for Disease...
Keep Reading →
June 18 - News
Abbott Laboratories (NYSE:ABT) seems to think its stock is cheap enough to justify sinking a substantial amount of its nest egg into the company's stock.
Keep Reading →
June 18 - News
The S&P 500 fell nearly 10% in June 2008, and investors began to brace for an eventual market crash later in the year.
Keep Reading →
June 17 - Stock Analysis
The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for...
Keep Reading →
June 17 - Stock Analysis
A new drug in the fight against cancer is certainly an exciting and welcome development.
Keep Reading →
June 17 - News
The latest drug to bite the dust is LY2886721, a beta secretase, or BACE, inhibitor.
Keep Reading →
June 17 - News
Investing in biotech stocks is relatively risky amid the volatility of the market. There are many factors that can greatly affect share trends and price performance.
Keep Reading →
June 13 - News
Celgene Corporation (NASDAQ:CELG) shares have soared more than 46% so far in 2013.
Keep Reading →
June 12 - News
Nearly every big pharma player has been hit with patent expirations that have hit hard on sales lately, and Merck & Co., Inc. (NYSE:MRK) is no exception. Merck & Co., Inc.
Keep Reading →
June 12 - News
Merck & Co., Inc. (NYSE:MRK) has been trying to generate more value for its shareholders via its share buyback program.
Keep Reading →
June 12 - News
After the announcement from the Bank of Japan that it will hold firm with its economic stimulus, the U.S. markets headed south.
Keep Reading →
June 12 - News
Pharmaceutical giant Merck & Co., Inc.
Keep Reading →
June 11 - News
Move over, Superman: There's a more unstoppable force that can leap even the highest expectations, and its name is the Dow Jones Industrial Average.
Keep Reading →
June 10 - News
Does Medicare have one foot in the grave already? The Trustees of the Medicare program recently announced that the program will remain solvent through 2026.
Keep Reading →
June 10 - News
Every week at The Motley Fool we reflect on the top stories in the biotech sector in a wrap-up column.
Keep Reading →
June 10 - News
A 2011 Nobel Prize in Physiology and Medicine is certainly impressive. Using a novel cancer treatment on yourself is both impressive and courageous. Dr.
Keep Reading →
June 10 - News
